Brief: Jasper Therapeutics Announces European Union Orphan Drug Designation For Briquilimab
04/01/2023 13:21
Jan 4 (Reuters) - Jasper Therapeutics Inc JSPR.O :
* JASPER THERAPEUTICS ANNOUNCES EUROPEAN UNION ORPHAN DRUG
DESIGNATION FOR BRIQUILIMAB AS A CONDITIONING TREATMENT FOR
PATIENTS PRIOR TO RECEIVING A STEM CELL TRANSPLANT
Source text for Eikon: ID:nGNX800jlL
Further company coverage: JSPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jasper Therapeutics
See all newsBrief: Jasper Therapeutics Announces Commencement Of An Offer To Purchase Outstanding Warrants
Jasper Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a share - Earnings Preview
Jasper Therapeutics rises; co announces all-stock merger with Kira Pharma